SMAD3 and small cell lung carcinoma: Similarly, it has been shown that increased expression of TGFβ1 and SMAD3, the downstream of TGFβ1, was associated with shorter PFS or OS in patients with SCLC who were treated with immune checkpoint inhibitors in the present study.